The landscape of receptor-mediated precision cancer combination therapy via a single-cell perspective

Saba Ahmadi¹², Pattara Sukprasert¹², Rahulsimham Vegesna³, Sanju Sinha³, Fiorella Schischlik³, Natalie Artzi⁴, Samir Khuller¹², Alejandro A. Schäffer³⁹ & Eytan Ruppin³⁹

Mining a large cohort of single-cell transcriptomics data, here we employ combinatorial optimization techniques to chart the landscape of optimal combination therapies in cancer. We assume that each individual therapy can target any one of 1269 genes encoding cell surface receptors, which may be targets of CAR-T, conjugated antibodies or coated nanoparticle therapies. We find that in most cancer types, personalized combinations composed of at most four targets are then sufficient for killing at least 80% of tumor cells while sparing at least 90% of nontumor cells in the tumor microenvironment. However, as more stringent and selective killing is required, the number of targets needed rises rapidly. Emerging individual targets include PTPRZ1 for brain and head and neck cancers and EGFR in multiple tumor types. In sum, this study provides a computational estimate of the identity and number of targets needed in combination to target cancers selectively and precisely.

https://doi.org/10.1038/s41467-022-29154-2

¹ Department of Computer Science, University of Maryland, College Park, MD 20742, USA. ² Department of Computer Science, Northwestern University, Evanston, IL 60208, USA. ³ Cancer Data Science Laboratory, National Cancer Institute, Bethesda, MD 20892, USA. ⁴ Department of Medicine, Engineering in Medicine Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02139, USA. ⁵ Broad Institute of Harvard and MIT, Cambridge, MA 02139, USA. ⁶ Institute for Medical Engineering and Science, MIT, Cambridge, MA 02139, USA. ⁷ Present address: Toyota Technological Institute at Chicago, Chicago, IL 60637, USA. ⁸These authors contributed equally: Saba Ahmadi, Pattara Sukprasert. ⁹These authors jointly supervised this work: Alejandro A. Schäffer, Eytan Ruppin. ♦email: alejandro.schaffer@nih.gov; eytan.ruppin@nih.gov
Personalized oncology offers hope that each patient’s cancer can be treated based on its genomic characteristics. Several trials have suggested that it is possible to collect genomics data fast enough to inform treatment decisions. Meta-analysis of Phase I clinical trials completed during 2011–2013 showed that overall, trials that used molecular biomarker information to influence treatment plans gave better results than trials that did not. However, most precision oncology treatments utilize only one or two medicines, and resistant clones frequently emerge, emphasizing the need to deliver personalized medicine as multiple agents combined.

Important opportunities to combine systems biology and design of nanomaterials have been recognized to deliver medicines in combination to overcome drug resistance and combine biological effects.

The design of future precision oncology treatments is very challenging, given the growing recognition that tumors typically have considerable intra-tumor heterogeneity (ITH) and thus need to be targeted with a combination of medicines such that as many as possible tumor cells are hit by at least one medicine. Our analysis is based on two recently emerging technologies: (1) the advancement of single-cell transcriptomics and proteomics measurements from patients’ tumors, which are anticipated to enter gradually into clinical use, and (2) the introduction of “modular” treatments that target specific overexpressed genes/proteins to recognize cells in a specific manner and then use either the T-cell immune response or a lethal toxin to kill the tumor cells preferentially. Here we briefly summarize previous related work on those treatments, before moving to present our approach.

We focus our analysis on genes encoding receptors on the cell surface, as these may be precisely targeted by any of at least six technologies, including CAR-T therapy, immunotoxins ligated to the surface, as these may be precisely targeted by any of at least six medicines, CAR-T therapy is based on two recently emerging technologies: (1) the advancement of single-cell transcriptomics and proteomics measurements from patients’ tumors, which are anticipated to enter gradually into clinical use, and (2) the introduction of “modular” treatments that target specific overexpressed genes/proteins to recognize cells in a specific manner and then use either the T-cell immune response or a lethal toxin to kill the tumor cells preferentially. Here we briefly summarize previous related work on those treatments, before moving to present our approach.

We focus our analysis on genes encoding receptors on the cell surface, as these may be precisely targeted by any of at least six technologies, including CAR-T therapy, immunotoxins ligated to antibodies, immunotoxins ligated to mimicking peptides, and conventional chemotherapy ligated to nanoparticles. These treatments are all termed “modular,” as they include one part that specifically targets the tumor cell via a gene/protein overexpressed on its surface and another part, the cytotoxic mechanism that kills the cells.

Two recent genome-wide analyses of modular therapies have focused on CAR-T therapy, so we focus first on this technology to put our work in context. In the original formulation, CAR-T therapy used one cell surface target that marks the cells of interest, such as CD19 as a marker for B cells. To date, CAR-T therapy has been effective in achieving remissions for some blood cancers, but less effective for solid tumors. MacKay et al. selected 533 targets that had low expression in single-cell data, and implemented a computational approach named MadHitter (after the Mad Hatter from Alice in Wonderland) to identify optimal precision combination treatments that target membrane receptors (Fig. 1A–C). We define three key parameters related to the stringency of killing the tumor and protecting the non-tumor cells and explore how the optimal treatments vary with those parameters (Fig. 1B, C, Supplementary Fig. 1). Solving this problem is analogous to solving the classical “hitting set problem” in combinatarial algorithms, which is formally defined in the “Methods” section (see also Supplementary Note 1 for an extensive introduction to related past work). Unlike the previous studies on CAR-T targets, we define the problem in a personalized manner, intending that each patient will get optimal treatments for their tumor from among a collection of treatments available at the cohort level.

Results

The data and the combinatorial optimization framework. We focused our analysis searching for optimal treatment combinations in nine single-cell RNA-seq data sets that include tumor cells and non-tumor cells from at least three patients that were publicly available at the onset of our investigation (“Methods” Table 1). Those data sets include four brain cancer data sets and...
one each from head and neck, melanoma, lung, breast and colon cancers. Most analyses were done for all data sets, but for clarity of exposition, we focused the main text analyses on four data sets from four different cancer types (brain, head and neck, melanoma, lung) that are larger than the other five and hence, make the optimization problems more challenging. The results for the other five data sets are provided in the Supplementary Notes.

To formalize our questions as combinatorial optimization hitting set problems, we define the following parameters and baseline values and explore how the optimal answers vary as functions of these parameters: We specify a lower bound on the fraction of tumor cells that should be killed, $lb$, which ranges from 0 to 1. Similarly, we define an upper bound on the fraction of non-tumor cells whose killing is tolerated, respectively. Baseline settings are $r = 2$, $lb = 0.8$, and $ub = 0.1$, and can be varied. The right side of (C) shows a hypothetical example of the tradeoff between killing tumor cells and sparing non-tumor cells. MadHitter would select target set B since only it satisfies both baseline settings.

To formalize our questions as combinatorial optimization hitting set problems, we define the following parameters and baseline values and explore how the optimal answers vary as functions of these parameters: We specify a lower bound on the fraction of tumor cells that should be killed, $lb$, which ranges from 0 to 1. Similarly, we define an upper bound on the fraction of non-tumor cells killed, $ub$, which also ranges from 0 to 1. To be...
concrete, our baseline settings are \( lb = 0.8 \) and \( ub = 0.1 \) but we also explore other values, and the approach (and code) are generic and can explore the landscape of solutions at any other settings deemed of interest. Therapies such as conjugated antibodies and nanoparticles are designed to recognize and kill cells that overexpress a target protein on the cell surface. To model quantitatively the overexpression associated with recognition of cells overexpressing the target, we introduced a parameter, \( r \), that designates the ratio of the mean overexpression of a given target in cancer vs non-cancer cells within the tumor microenvironment. The expression ratio \( r \) defines which cells are killed, as follows (Fig. IB): Denote the mean expression of a gene \( g \) in non-cancer cells that have non-zero expression by \( E(g) \). A given cell is considered killed if gene \( g \) is targeted and its expression level in that cell is at least \( r \times E(g) \). Higher values of \( r \) thus model more selective killing.

Having \( r \) as a modifiable parameter anticipates that in the future one could experimentally tune the overexpression level (see Supplementary Note 1) at which cell killing occurs\(^{21} \). In this respect, technologies that rely on RME to get a toxin into the cell are particularly tunable because there is known to be a non-linear relationship, called “superselectivity” between the number of protein copies on the cell surface and the probability that RME occurs successfully\(^{34} \). In these technologies, the toxin or other therapy delivered by the modular treatment enters cells in a gene-specific manner\(^{35} \). CAR-T therapy activates T-cell killing against cells in a gene-specific manner\(^{22,21} \).

The question of how sharp a non-linear superselective jump in ligand-receptor binding as a function of surface density of receptors is achievable in a nanoparticle system has been the focus of both experimental and theoretical studies for nanoparticles and CAR-T, as reviewed in Supplementary Note 1. The applicability across technologies, we model a framework in which each nanoparticle has multiple copies of one ligand attached and the distinct nanoparticles act in a logical OR fashion. Combining superselectivity with a statistical mechanics analysis, Tian and colleagues validated an alternative logical OR framework in which multiple ligands are attached to a single nanoparticle; importantly, they validated this heterogeneous logical OR framework using ligands for the proteins encoded by the human genes LRP1 and SCARB1\(^{36} \).

Table 1 Summary descriptions of single-cell data sets from solid tumors used either for analysis (9) or preliminary testing (5 additional) and one liquid tumor data set used for validation (1 additional).

| Data set code | Cancer type(s) | Cancer cells (patients) | Non-cancer cells (patients) | Clinical follow-up | Ref. |
|---------------|----------------|-------------------------|-----------------------------|-------------------|-----|
| GSE7688       | Breast         | 441 (11)                | –                           | Metastasis or not | 93  |
| GSE18389      | Breast         | 804 (6)                 | 314 (6)                     | Metastasis or not | 72  |
| GSE89567      | Brain (glioma) | 5097 (10)               | 1146 (9)                    | No                | 94  |
| GSE103224     | Brain (glioma) | 23793 (8)               | –                           | No                | 71  |
| GSE70630      | Brain (glioma) | 4044 (6)                | 303 (6)                     | No                | 95  |
| GSE75872      | Brain (glioma) | 440 (6)                 | –                           | No                | 96  |
| GSE102130     | Brain (glioma) | 2858 (9)                | 94 (5)                      | No                | 97  |
| GSE84465      | Brain (glioma) | 1091 (4)                | 651 (4)                     | No                | 46  |
| GSE1861       | Colorectal     | 272 (10)                | 160 (6)                     | No                | 98  |
| GSE103222     | Head and neck  | 2093 (13)               | 3197 (15)                   | No                | 99  |
| GSE115978     | Melanoma       | 2018 (23)               | 4334 (32)                   | Yes, immuno-therapy | 91,92 |
| GSE118828     | Ovarian        | 1415 (11 primary)       | 578 (2)                     | No                | 100 |
| GSE67980      | Prostate       | 124 (21)                | –                           | Metastasis or not | 101 |
| E-MTAB-6149   | Lung           | 7351 (5)                | 2730 (5)                    | No                | 102 |
| GSE32509      | Acute lymphoblastic leukemia (ALL) | 21329 (6 B-ALL) | 4744 (6 B-ALL) | No | 38 |

Data sets are ordered so that those from the same or similar tumor types are on consecutive rows. The first 13 and 15th data sets were obtained either from GEO or the Broad Institute Single Cell Portal, but the GEO code is shown. The data set on the 14th row was obtained from ArrayExpress. In some data sets that have both cancer and non-cancer cells, there may be patients for whom only one type or the other is provided. Hence, the numbers in parentheses in the third and fourth columns may differ. In most cases, the number of patients we analyzed is the minimum of the two numbers in parentheses; for example, for GSE103222, we analyzed data on 13 patients, which is the minimum of (13) and (15). Data set GSE103222\(^{19} \) superseded and partly subsumes GSE720569\(^{22} \). For the blood cancer data set, we used only the six samples from B-acute lymphoblastic leukemia (ALL) patients and report only those cells as counted in the version at (https://tcshc.com pensions.org); the data set also contains samples from two patients with T-cell ALL and three healthy donors that we did not analyze.

Given these definitions, we solve the following combinatorial optimization hitting set problem (“Methods”): Given an input of a single-cell transcriptomics sample of non-tumor and tumor cells for each patient in a cohort of multiple patients, bounds \( ub \) and \( lb \), ratio \( r \), and a set of target genes, we seek a solution that includes a minimum-size combination of targets in each individual patient, while additionally minimizing the size of all targets given to the patient cohort. The latter is termed the global minimum-size hitting set (GHS) in computer science terminology or the cohort target set (CTS) in terminology specific to our problem, while the optimal hitting set of genes targeting one patient is termed the individual target set (ITS). This optimum hitting set problem with constraints can be solved to optimality using integer linear programming (ILP) (“Methods”, Supplementary Fig. 2). We solve different optimization problem instances, each of which considers a different set of candidate target genes: 1269 genes encoding cell surface receptor proteins, and subset of 58 out of these 1269 genes that already have published ligand-
mimicking peptides, and a nested collection of sets of 424–900 out of the 1269 genes that are lowly expressed across normal human tissues below a series of decreasing gene expression thresholds. From a computational standpoint, there is no inherent theoretical limit on the size of the candidate gene set, but in practice, such optimization tasks may become intractable as this size increases. Our formulation is personalized as each patient receives the minimum possible number of treatments. The global optimization comes into play only when there are multiple solutions of the same size to treat a patient. For example, suppose we have two patients such that patient A could be treated by targeting either \( \{ \text{EGFR, FGF2} \} \) or \( \{ \text{MET, FGF2} \} \) and patient B could be treated by targeting either \( \{ \text{EGFR, CD44} \} \) or \( \{ \text{ANPEP, CD44} \} \). Then we prefer the CTS \( \{ \text{EGFR, FGF2, CD44} \} \) of size 3 and we treat patient A by targeting \( \{ \text{EGFR, FGF2} \} \) and patient B by targeting \( \{ \text{EGFR, CD44} \} \).

As the number of cells per patient varies by three orders of magnitude across data sets, we use random sampling to obtain hitting set instances of comparable sizes that adequately capture tumor heterogeneity. We found that sampling hundreds of cells from the tumor is sufficient to get enough data to represent all cells. In most of the experiments shown, the number of cells sampled, which we denote by \( c \), was 500. In some smaller data sets, we had to sample smaller numbers of cells (“Methods”). As shown in Supplementary Note 2, Supplementary Figs. 2, 3), 500 cells, when available, are roughly sufficient for CTS size to plateau for our baseline parameter settings, \( lb = 0.8, ub = 0.1, r = 2.0 \). The results using all cells and default parameters are shown in Supplementary Table 1 and are similar to the results using sampling, where we consider the latter more informative for future studies. Hence, for each individual within a data set, we performed independent sampling of \( c \) cells 20 times and their results were summarized.

Cohort and individual target set sizes as functions of tumor killing and non-tumor sparing goals. Given the single-cell tumor data sets and the ILP optimization framework described above, we first studied how the resulting optimal cohort target set (CTS) may vary as a function of the parameters defining the optimization objectives in different cancer types. Figure 2 and Supplementary Figs. 4–8 in Supplementary Note 3 show heat-maps of CTS sizes when varying \( lb, ub \), and \( r \) around the baseline values of 0.8, 0.1, and 2.0, respectively. The CTS sizes for melanoma were largest, partly due to the larger number of patients in that data set (Table 1). Indeed, as we sampled subsets of 5 or 10 patients uniformly and observed that the mean CTS sizes grew from 7.9 (5 patient subsets) to 12.3 (10 patient subsets) to 31.0 (all patients, as shown in Fig. 2).

Encouragingly, for most data sets and parameter settings, the optimal CTS sizes are in the single digits. However, in several data sets, we observe a sharp increase in CTS size as \( lb \) values are increased above 0.8 and/or as the \( ub \) is decreased below 0.1, with a more pronounced effect of varying \( lb \). This transition is more discernable at the lowest value of \( r \) (1.5), probably because when \( r \) is lower, it becomes harder to find genes that are individually selective in killing tumor cells and sparing non-tumor cells (Supplementary Figs. 4–8). The qualitative transition observed in CTS sizes occurs robustly regardless of the threshold for filtering out low expressing cells when preprocessing the data (Supplementary Note 4, Supplementary Figs. 9–11).

We next examined what are the resulting individual target set (ITS) sizes obtained in the optimal combinations under the same conditions. In all data sets, the mean ITS sizes are in the single digits for most values of \( lb \) and \( ub \). The distributions of ITS sizes are shown for four data sets and two combinations of \( \{ lb, ub \} \) (Fig. 3) and for additional data sets in Supplementary Note 5 (Supplementary Fig. 12). Overall, the mean ITS sizes with the baseline parameter values \( (r = 2.0, lb = 0.8, ub = 0.1) \) range from 1.0 to 3.91 among the nine data sets studied (Supplementary Table 3); on average 4 targets per patient should hence suffice if enough single-target treatments are available in the cohort target set. However, there is considerable variability across patients.

Evidently, as we make the treatment requirements more stringent (by increasing \( lb \) from 0.8 to 0.9 and decreasing \( ub \) from 0.1 to 0.05), the variability in ITS size across patients became larger. Importantly, this analysis provides rigorous quantifiable evidence grounding the prevailing observation that among tumors of the same type, some individual tumors may be much harder to treat than others. Taken together, these results show that we can compute precise estimates of the number of targets needed for cohorts (in the tens) and individual patients (in the single digits usually) and that these estimates are sensitive to the killing stringency, especially when the \( lb \) increases above 0.8. The variation for more aggressive killing regimes, with values of \( lb \) up to 0.099 for the baseline \( r = 2.0 \) is displayed in Supplementary Figs. 13 and 14 in Supplementary Note 6. For fixed \( lb = 0.8, ub = 0.1 \) and varying \( r \), to values as high as 5.0, smallest CTS sizes are typically obtained for \( r \) values close to 2.0, further motivating our choice of \( r = 2 \) as the default value (Supplementary Note 7, Supplementary Figs. 15 and 16, Supplementary Table 2). Finally, we show that, as expected, a ‘control’ greedy heuristic algorithm searching for small and effective target combinations finds ITS sizes substantially larger than the optimal ITS sizes identified using our optimization algorithm (Fig. 3). The greedy CTS size is greater than the ILP optimal CTS size for eight out of nine data sets (Supplementary Table 3 in Supplementary Note 8, “Methods”). The comparison between heuristic and optimal solutions is of interest because it quantifies the benefit of finding the optimum-size ITS and CTS and the previous related studies reviewed in the Introduction used only heuristic methods for solution sizes above 2 or 3, respectively.

The landscape of combinations achievable with receptors currently targetable by published ligand-mimicking peptides or those tested in CAR-T trials. To get a view of the combination treatments that are possible with receptor targets for which there are already existing modular targeting reagents, we conducted a literature search identifying 58 out of the 1269 genes with published ligand-mimicking peptides that have been already tested in vitro models, usually cancer models (“Methods”; Tables 3 and 4). We asked whether we could find feasible optimal combinations in this case and if so, how do the optimal CTS and ITS sizes compare vs. those computed for all 1269 genes?

Computing the optimal CTS and ITS solutions for this basket of 58 targets, we found feasible solutions for six of the data sets across all parameter combinations we surveyed and three of these six are illustrated for each patient in Fig. 4. However, for three data sets, in numerous parameter combinations we could not find optimal solutions that satisfy the optimization constraints (Supplementary Notes 9, Supplementary Figs. 17–19). That is, the currently available targets do not allow one to design treatments that may achieve the specified selective killing objectives, underscoring the need to develop new targeted cancer therapies, to make personalized medicine more effective for more patients.

Overall, comparing the optimal solutions obtained with 58 targets to those we have obtained with the 1269 targets, three qualitatively different behaviors are observed (Supplementary Notes 9, Supplementary Figs. 17–19): (1) In some data sets, it is just a little bit more difficult to find optimal ITS and CTS
solutions with the 58-gene pool, while in others, the restriction to a smaller pool can be a severe constraint making the optimization problem infeasible. (2) The smaller basket of gene targets may force more patients to receive similar individual treatment sets and thereby reduces the size of the CTS. (3) Unlike the CTS size, the ITS size must stay the same or increase when the pool of genes is reduced, because we find the optimal ITS size for each patient. Overall, the average ITS sizes across each cohort using the pool of 58 genes for baseline settings range from 1.16 to 4.0. Among cases that have any solution, the average increases in the ITS sizes at baseline settings in the 58 genes case vs. that of the 1269 case were moderate, ranging from 0.16 to 1.33.

We performed a similar analysis with 57 gene targets that were listed as the genes encoding single proteins in CAR-T trials (Supplementary Table 4; see one visualization of the results in Supplementary Fig. 20). However, using our baseline parameter settings and either with cell sampling or analyzing all cells together only three out of nine data sets have feasible solutions because the majority of the CAR-T target genes were filtered out by the researchers who collected the primary data. Those include brain cancer GSE89567 (mean CTS 2.95, ITS 1), brain cancer GSE102130 (mean CTS 4, ITS 2), and breast cancer GSE118389 (mean CTS 7, ITS 3). This limited success suggests that, to cover brain cancers GSE89567 (mean CTS 2.95, ITS 1), brain cancer GSE102130 (mean CTS 4, ITS 2), and breast cancer GSE118389 (mean CTS 7, ITS 3). This limited success suggests that, to cover

Optimal fairness-based combination therapies for a given cohort of patients. Until now we have adhered to a patient-centered approach that aims to find the minimum-size ITS for each patient, first and foremost. We now study a different, cohort-centered approach, where given a cohort of patients, we seek to minimize the total size of the overall CTS size, while allowing for some increase in the ITS sizes. The key question is how much larger are the resulting ITS sizes if we optimize for minimizing the cohort (CTS) size, rather than the individuals (ITS) size? This challenge is motivated by a ‘fairness’ perspective (Supplementary Note 1), where we seek solutions that are beneficial for the entire community from a social or economic perspective (in terms of CTS size) even if they are potentially suboptimal at the individual level (in terms of ITS sizes). Here, the potential benefit is economic since running a basket trial would be less expensive if one reduces the size of the basket of available treatments (Fig. 5A, B).

We formalized this ‘fair CTS problem’ by adding a cost parameter $\alpha$ that specifies the limit on the excess number of (ITS) targets selected for any individual patient, compared to the number selected in the individual-based approach that was studied up until now (formally, the latter corresponds to setting $\alpha = 0$). We formulated and solved via ILP this fair CTS problem samples, we found that a mean of 80.3% per patient of malignant cells express CD19 (“Methods”). This result is consistent with the 0.8 baseline value of $lb$ we have used throughout the paper. The annotations of the non-malignant cells were not sufficiently consistent to assess the 0.1 baseline value of $ub$. Notably, blood cancers are fundamentally different from solid tumors. A different line of support for the choice of the 0.8 threshold is provided in “Methods”.

Fig. 2 Heatmaps showing how the cohort target set (CTS) size varies as a function of $lb$, $ub$, $r$, and across data sets. For each plot the x-axis and y-axis represent $lb$ and $ub$ parameter values, respectively. The scale on the right shows the cohort target set sizes by color scale. We show separate plots for $r = 2, 3$ here and a larger set (1.5, 2.0, 2.5, 3.0) in Supplementary Note 3. Individual values are not necessarily integers because each value represents the mean of 20 replicates of sampling c (500 for each of the data sets shown here) cells (Supplementary Fig. 2). Source data are provided as a Source data file.
for up to 1269 possible targets on all nine data sets ("Methods"). We fixed \( r = 2 \) and \( ub = 0.1 \) while varying \( a \) and \( lb \). Figure 5C and Supplementary Figs. 21–25 in Supplementary Note 10 show the optimal CTS and ITS sizes for \( a = 0, ..., 5 \).

For 8 out of 9 data sets, we encouragingly find that the unfairness cost parameter \( a \) is bounded by a constant of 3; i.e., it is sufficient to increase \( a \) by no more than 3 to obtain the smallest CTS sizes in the optimally fair solutions. For the largest data set (melanoma), \( a = 4 \). As we show in Supplementary Note 10, empirically, even if one requires lower \( a \) values, then as those approach 0, the size of the fairness-based CTS grows fairly moderately and remains in the lower double digits, and the mean size of the number of treatments given to each patient (their ITS) is overall <5. Theoretically, we show that one can design instances for which \( a \) would need to be at least \( \sqrt{n} - 1 \) to get a CTS of size less than the overall number of targets \( n \) (Supplementary Note 10). However, in practice, we find that given the current tumor single-cell expression data, fairness-based treatment strategies are likely to be a reasonable economic option in the future.

The landscape of optimal solutions targeting differentially expressed tumor receptors that are lowly expressed across many healthy tissues. We turn to examine the space of optimal solutions when restricting the set of eligible surface receptor gene targets to those that have lower expression across many non-cancerous human tissues ("Methods"), aiming to mitigate potential damage to tissues unrelated to the tumor site. To this end, we selected subsets of the 1269 cell surface receptor targets in which the genes have overall lower expression across multiple normal tissues, by mining GTEx and the Human Protein Atlas (HPA) ("Methods"). Varying the selectivity expression thresholds (expressed in transcripts per million (TPM)) used to filter out genes whose mean expression across the normal adult tissues is above values of 10, 5, 2, 1, 0.5, and 0.25 (i.e., employing more and more extensive filtering as this threshold is decreased), decreases the size of the target cell surface receptor gene list by more than half (Table 2).

As shown in Fig. 6A, B (and Supplementary Figs. 26–28), MadHitter identifies very different cohort target sets (which are larger than the original optimal solutions, as expected) as the...
TPM selectivity threshold value may become infeasible. At an individual patient level, using lower selectivity threshold levels, which leads to a smaller space of membrane receptors to choose from, also leads to increased mean ITS sizes (Supplementary Figs. 30, 31). Across the nine data sets, the selectivity threshold levels, which leads to a smaller space of membrane receptors to choose from, also leads to increased mean ITS sizes (Supplementary Figs. 30, 31). Across the nine data sets, the selectivity threshold at which the CTS problem became infeasible varied (Supplementary Fig. 29). The differences observed could be the result of expression heterogeneity of the cancer, number of patients within the data set, size of target gene set, lack of expression of available gene targets, and other unknown factors. In the future, further experimentation is required to identify tissue-specific optimal gene expression thresholds that will minimize side effects while allowing cancer cells to be killed by combinations of targeted therapies. Finally, for completeness, we also tested MadHitter on the set of 533 lowly expressed genes suggested by MacKay et al. All instances with default setting of $r, lb, ub$ have feasible solutions for all patients. Mean ITS sizes are below 4 for eight of nine data sets, but close to 10 for the brain cancer data set GSE84465. More details can be found in Supplementary Note 11 and Supplementary Table 5.

**Key targets composing optimal solutions across the space of 1269 membrane receptors.** To identify the genes that occur most often in optimal solutions for our baseline settings, since there may be multiple distinct optimal solutions composed of different target genes, we sampled up to 50 optimal solutions for each optimization instance solved and recorded how often each gene occurs and how often each pair of genes occur together ("Methods"). We analyzed and visualized these gene (co-)occurrences in three ways. First, we constructed co-occurrence cirkos plots in which arcs around the circle represent frequently occurring genes and edges connect targets that frequently co-occur in optimal CTS solutions. Figure 6C–F shows the co-occurrence visualizations for optimal CTS solutions obtained with the original, unfiltered target space of 1269 genes and in baseline parameter settings. The genes frequently occurring in optimal solutions are quite specific and distinct between different cancer types. In melanoma, the edges form a clique-like network because virtually all optimal solutions include the same clique of 12 genes (Fig. 6E). The head and neck cancer data set has only one commonly co-occurring pair {GPR87, CXADR}, partly because the CTS sizes are much smaller, ranging from 2 to 5, and the optimal solutions of sizes larger than 2 vary substantially in the choices of the other gene(s) (Fig. 6D). The choices of these two genes are not obvious as CXADR ranks only 10th by our measure of gene overexpression (Supplementary Note 8) and GPR87 is not in the top 20 genes. Of the cancer types not depicted in Fig. 6, the breast cancer data set has a commonly co-occurring set of size 4, {CLDN4, INSR, P2RY8, SORL} none of which ranks in the top 20 genes, and the colorectal cancer data set has a different co-occurring set of size 4, {GABRE, GPRR, LGR5, PTPRJ}. These variations should be viewed as characteristic of different data sets, not of different tumor types, since we see different results for the four brain cancer data sets.

We next tabulated sums of how often each gene occurred in optimal solutions for all nine data sets (Supplementary Note 12, Supplementary Tables 6, 7 and 8), obtained when solving for either 58 gene targets or 1269 gene targets. Strikingly, one gene, PTPRZ1 (protein tyrosine phosphatase receptor zeta 1), appears far more frequently than others, especially in three brain cancer data sets (GSE70630, GSE89567, GSE102130, Supplementary Table 8). PTPRZ1 also occurs commonly in optimal solutions for the head and neck cancer data set (Fig. 6D). The brain cancer finding coincides with previous reports that PTPRZ1 is over-expressed in glioblastoma (GBM). PTPRZ1 also forms a fusion with the nearby oncogene MET in some brain tumors that
have an overexpression of the fused MET.\textsuperscript{41} Notably, various cell line studies and mouse studies have shown that inhibiting PTPRZ1, for example by shRNAs, can slow glioblastoma tumor growth and migration\textsuperscript{42,43}. There have been some attempts to inhibit PTPRZ1 pharmacologically in brain cancer and other brain disorders\textsuperscript{44,45}. In the four brain cancer data sets, PTPRZ1 is expressed selectively above the baseline $r = 2.0$ in 0.99 (GSE89567), 0.84 (GSE70630), 0.96 (GSE102130), and 0.27 (GSE84465) proportion of cells in each cohort. The much lower relative level of PTPRZ1 expression in GSE84465 is likely due to the heterogeneity of brain cancer types in this data set\textsuperscript{46}. Among the 58 genes with known ligand-mimicking peptides, EGFR stands out as most common in optimal solutions (Supplementary Table 6). Even when all 1269 genes are available, EGFR is most commonly selected for the brain cancer data set (GSE84465) in which PTPRZ1 is not as highly overexpressed (Fig. 6C).

PTPRZ1 was the fifth most frequently occurring gene in optimal solutions for the head and neck cancer data set. Let us assume that each of three patients has two tumor cells (columns), each displaying five membrane receptors that are highly expressed only on the tumor cells and not on the non-tumor ones (rows). If we target \{APP, MET\} (panel A, cost unfairness parameter $\alpha = 1$) in all patients, then this achieves a cohort target set (CTS) size of 2, which is the minimum possible. Employing the original individual-based optimizing objective, each patient could instead be treated by an individual target set (ITS) of size 1 by targeting the distinct receptors called Target 1 (specific to patient 1), Target 2, and Target 3, respectively, but this would result in an optimal CTS of size 3 (panel B, cost unfairness parameter $\alpha = 0$). The solution in panel A has an unfairness value $\alpha = 1$ because the worst difference among all patients is that a patient receives 1 more treatment than necessary. C Heatmaps showing how the CTS size varies as $\alpha$ increases (y-axis), starting from its baseline value of 0 where each patient is assigned a minimum-sizes individual treatment set (top row). The lower bound on tumor cells killed (x-axis) is also varied while the upper bound on non-tumor cells killed is kept fixed at 0.1. We are particularly interested in finding the smallest value on the y-axis at which the CTS size reaches its minimum value, which is circled for the baseline $lb = 0.8$, because this bounds the tradeoff between the achievable reduction in the number of targets needed to treat the whole cohort and the number of extra targets above the ITS minimum that any patient might need to receive. Source data for panel C are provided as a Source data file.
CXADR was found to play a role in regulating PTEN in the AKT human tissues, for different tumor types. A

| Thresholds expression across tissues (TPM) | Size of gene set (OR*) | No of genes which are NOT olfactory receptors (TAS*) | No of genes with ligand-mimicking peptides (intersection with Tables 3 and 4) |
|-------------------------------------------|------------------------|--------------------------------------------------|--------------------------------------------------|
| 0.25                                      | 424                    | 97                                               | 1                                                |
| 0.5                                       | 494                    | 141                                              | 3                                                |
| 1                                         | 547                    | 187                                              | 3                                                |
| 2                                         | 632                    | 269                                              | 6                                                |
| 5                                         | 762                    | 398                                              | 10                                               |
| 10                                        | 900                    | 536                                              | 19                                               |

Fig. 6 Variation in the cohort target set (CTS) size and composition as function of the magnitude of filtering threshold ("Methods"), for (A) breast cancer and (B) brain cancer. These data sets were selected due to their relatively small cohort target set sizes, permitting their visualization. C-F Circos plots of the genes occurring most frequently in optimal CTS solutions (length of arc along the circumference) and their pairwise co-occurrence (thickness of the connecting edge) for the four main cancer types, in our original target space of 1269 encoding cell-surface receptors. For each data set, we sampled up to 50 optimal CTS solutions. Co-occurrence representations of the 12 most common target genes out of 1269 encoding cell-surface receptors (with >5% frequency of occurrence) are represented in a cancer-specific manner for (C) breast cancer, (D) head and neck cancer (only seven genes have a frequency of 5% or more across optimal solutions), (E) melanoma, and (F) lung cancer. Genes and connections have distinct colors for improved visibility. Source data are provided as a Source data file.

(GSE103322). The two most common genes by a large margin are CXADR and GPR87. CXADR has been studied primarily by virologists and immunologists because it encodes a receptor for coxsackieviruses and adenoviruses47. In one breast cancer study, CXADR was found to play a role in regulating PTEN in the AKT pathway, but CXADR was underepressed in breast cancer48 whereas it is overexpressed in the head and neck cancer data we analyzed. GPR87 is a rarely studied G protein-coupled receptor with unknown natural ligand49. In the context of cancer, GPR87 has previously been reported as overexpressed in several tumor types including lung and liver49 and its overexpression may play an oncogenic role via either the p53 pathway50, the NFκB pathway51 or other pathways.

Finally, we analyzed the set of genes in optimal solutions via the STRING database and associated tools52 to perform several types of gene set and pathway enrichment analyses. Supplementary Figs. 32–35 (Supplementary Note 12) show STRING-derived protein–protein interaction networks for the 25 most common genes in the same four data for which we showed co-occurrence graphs in Fig. 6C–F. Again, EGFR stands out as being a highly...
connected protein node in the solution networks for both the brain cancer and head and neck cancer data sets. Among the 30 genes in the 1269-gene set that occur most commonly in optimal solutions (Supplementary Table 7), there are six kinases (out of 88 total human transmembrane kinases with a catalytic domain, STRING gene set enrichment $p<1e^{-6}$, namely \{EGFR, EPHB4, ERBB3, FGFR1, INSR, NTRK2\} and two phosphates \{PTPRJ, PTPRZ1\}. The KEGG pathways most consistently enriched, all at FDR<0.005, are (“proteoglycans in cancer”) represented by \{CD44, EGF, ERBB3, FGFR1, PLAUR\}, (“adherens junction”) represented by \{EGFR, FGFR1, INSR, PTPR\}, and (“calcium signaling pathway”) represented by \{EDNRB, EGF, ERBB3, GRPR, P2RX6\}. The one gene in the intersection of all these pathways and functions is EGFR.

**Discussion**

In this multi-disciplinary study, we harnessed techniques from combinatorial optimization to analyze publicly available single-cell tumor transcriptomics data to chart the landscape of future personalized combinations that are based on modular therapies, including CAR-T therapy. We showed that, for most tumors we studied, four modular medications targeting different over-expressed receptors may suffice to selectively kill most tumor cells, while sparing most of the non-cancerous cells (Figs. 2 and 3 and Table S3). For the more restricted sets of low-expression genes\(^{22}\) or the 58 receptors with validated ligand-mimicking peptides (Tables 3 and 4), some patients do not have feasible solutions, especially as we reduce the TPM expression used for filtering the gene set to avoid targeting non-cancerous tissues. These findings indicate, on one hand, that researchers designing ligand-mimicking peptides have been astute in choosing targets relevant to cancer. On the other hand, these results suggest that there is a need for extending the set of cell surface receptors that can be targeted to enter tumor cells with ligated chemotherapty agents. There are two established methods to identify ligand-mimicking peptides called “one bead one compound” and “phage display”\(^{20}\), the latter of which was awarded the 2018 Nobel Prize in Chemistry. Both methods are applicable to all cell surface proteins and thus, we believe that the set of proteins with validated peptides could be greatly expanded as nanoparticle-based treatments get closer to being used in the clinic.

Remarkably, we found that if one designs the optimal set of treatments for an entire cohort adopting a fairness-based policy, then the size of the projected treatment combinations for individual patients are at most 3 targets larger, and in most data sets at most 1 target receptor larger than the optimal solutions that would have been assigned for these patients based on an individual-centric policy (Fig. 5, Supplementary Note 10). This suggests that the concern that the personalized treatment for any individual will be sub-optimal solely because that individual happens to have registered for a cohort trial appears to be tightly bounded.

We had three principal motivations for treating each set of patients as a formal cohort. First and foremost, clinical trials are very expensive, and we are interested in what economies of scale can be found. Second, “basket trials”, such as the WINTher trial\(^{53}\) and the UMIN000016794 trial\(^{54}\) in which there are broad eligibility criteria and different patients receive different treatment based on an algorithm, have started; we think that such basket trials will be increasingly important to realize personalized oncology. Thirdly, the optimization problem that favors reusing gene targets for different patients may be of interest to algorithmically inclined readers, and may perhaps be useful in other applications.

Like the study of MacKay et al.\(^{22}\), our study is a conceptual computational investigation. As in the studies of Dannenfelser et al.\(^{21}\) and MacKay et al.,\(^{22}\) we assumed that treatment selection will be based on measuring gene expression; neither we nor they considered the possibility of treatments that target mutant proteins. Our framework could accommodate mutant proteins, if mutations are called from the single-cell mRNA reads, but this is challenging since the reads usually do not cover full mRNAs. That our framework captures some general aspects of conjugated antibodies, nanoparticles, and CAR-T as distinct treatment technologies is on one hand a strength because it is general, and on the other hand a weakness because we ignore various technology-specific issues that require further study. A simple example of a distinction is that CAR-T can have any cell surface protein as a target while conjugated antibodies and nanoparticles require a cell-surface protein that is a receptor that functions by binding of a ligand to unintended receptors.\(^{35,55}\) If these parameters were measured for a variety of ligands and receptors, then such data would open the possibility of a variety of heterogeneous nanoparticle designs including multiple ligands and decoy receptors being placed on single nanoparticles\(^{35,55}\). Our methods and software present combinatorial optimization as one basis for addressing these more complex challenges, but other forms of mathematical optimization could be further helpful in identifying the most potent and selective nanoparticle designs from an exponentially large space of possibilities, considering more refined properties of the specific nanoparticle conjugates in hand.

We have focused on developing methods based on analyzing single-cell transcriptomics data because it is the predominant current technology to collect abundant data on single cells of different types in a tumor’s microenvironment on a large scale.\(^{56}\) A key motivation for our study was the observation that single-
cell transcriptomics is not yet used in the clinic, and our hope is that demonstrating its potential value for identifying tumor cells specific treatment targets may possibly facilitate the collection and analysis of such data by clinicians and bioinformaticians for advancing patients treatment. As such, our work is a starting point. In the future, numerous additional omics technologies should be brought in to deeply and carefully identify the best treatments, that also would need to be carefully tailored according to the specific treatment modality (as CAR-T, conjugate antibodies, nanoparticles, etc. each has its own properties). Those include transcriptomics data with spatial information, single-cell proteomics, and other immunoprofiling/imaging methods, that may supplant transcriptomics as the method of choice for single-cell genomics data collection, as they become available on a large scale.

We studied nine data single-cell expression data sets here, but it would be helpful to analyze more and larger data sets in the future. Even among four data sets of the same (brain) cancer type, we observed considerable variability in CTS and ITS sizes. Since our approach is general and the software is freely available as source code, other researchers can test the method on new data sets or add new variables, constraints, and optimality criteria. For example, we chose to analyze each single cell as a unit; many analyses of scRNA cancer data choose to cluster the cells instead of using cell clusters as the units of analysis. In that view, analysis of differential gene expression is usually done between clusters, while we preferred to compare the expression of each gene in each cell to the expression of the same gene in all non-cancer cells. Our investigation may lead others to further improve our approach considering the stochastic nature of the expression of different genes measured, possibly preferring targets whose expression is more stable.

We compared gene expression levels between non-cancer cells and cancer cells sampled from the same patient, which avoids inter-patient expression variability. Following recent systematic efforts that have concluded that employing imputation in the analysis of single-cell RNA-seq data has no clear benefits as the zeroes observed in the data reflects both true gene expression and measurement error, we chose to avoid an imputation step in our study. Of course, others may take different decisions and include imputation in preprocessing the input data in future studies. As this investigation combines complex concepts from different scientific disciplines, we strived for simplicity in our modeling; therefore, we have taken the measured gene expression values as is, but future studies may consider extending our approach considering the stochastic nature of the expression of different genes measured, possibly preferring targets whose expression is more stable.

Even though the combinatorial optimization problems solved here are in the worst-case exponentially hard (NP-complete in computer science terminology), the actual instances that arise from the single-cell data could be either formally solved to optimality or shown to be infeasible with modern optimization software on the NIH Biowulf system, which has a hard limit of 240 wall-clock hours for any job. Of note, Delaney et al. have recently formalized a related optimization problem in analysis of single-cell clustered data for immunology. Their optimization problem is also NP-complete in the worst-case and they could solve sets of up to size four using heuristic methods. We have shown that the optimal ILP solutions we obtained are often substantially smaller than solutions obtained via a greedy heuristic (Fig. 3, Supplementary Note 8 including Supplementary Table 3).

### Table 4 Single proteins that can be targeted by ligand-mimicking peptides but are not included in the two principal reviews that we consulted and are among 1269 cell surface receptors.

| Protein                          | Gene symbol | At least one PubMed ID |
|----------------------------------|-------------|------------------------|
| ActRIIB                          | ACVR2B      | 28955765               |
| CD163                            | CD163       | 27563889               |
| CXCR4                            | CXCR4       | 19482312, 22523575     |
| Ephrin A4                        | EPHA4       | 15681844, 22523575     |
| Ephrin B1                        | EPHB1       | 15722342, 22523575     |
| Ephrin B2                        | EPHB2       | 15722342, 22523575     |
| Ephrin B3                        | EPHB3       | 15722342, 22523575     |
| Gonadotrophin releasing hormone receptor | GNRHR     | 20814857, 22523575     |
| G Protein-coupled receptor 55    | GPR55       | 28029647               |
| Bombesin receptor 2              | GRPR        | 20814857, 22523575     |
| IL4 receptor                     | IL4R        | 19012727               |
| Low-density lipoprotein receptor | LDLR        | 27656777               |
| Leptin receptor                  | LEPR        | 19232229, 26265355     |
| LRPI                             | LRPI        | 29090274               |
| Melanocortin 1 receptor          | MC1R        | 22964391               |
| Melanocortin 4 receptor          | MC4R        | 17591746               |
| CD206                            | MRC1        | 30768279               |
| Urokinase plasminogen activator receptor | PLAUR  | 25080049               |
| Neurokinin-1 receptor            | TACR1       | 29498264               |
| VPAC2                            | VIPR2       | 30077368               |

*Since the evidence that these 20 genes have ligand-mimicking peptides is scattered in the literature, we include at least one PubMed ID of a paper describing a suitable peptide. Gene symbols are in italics because that is the convention in human genetics.*
On the caudal side, experiments with target gene sets that were further filtered by low expression in normal tissues showed that the individual target set problem can become infeasible in many instances. Even when the instance remained feasible, optimal cohort treatment set sizes increased rapidly as the expression levels allowed decreased (Fig. 6), pointing to potential inherent limitations of applying such combination approaches to patients in the clinic and the need to carefully monitor their putative safety and toxicity in future applications. Finally, functional enrichment analysis of genes commonly occurring in the optimal target sets reinforced the central role of the widely studied oncogene **EGFR** and other transmembrane kinases. We also found that the less-studied phosphatase **PTPRZ1** is a useful target, especially in brain cancer.

In summary, this study harnesses combinatorial optimization tools to analyze emerging single-cell data to portray the landscape of feasible personalized combinations in cancer medicine. Our findings uncover promising membranal targets for the development of future oncology medicines that may serve to optimize the treatment of cancer patient cohorts via several cancer types. The MadHitter approach and the accompanying software module can be readily applied to address additional fundamentally related research questions and analyze additional cancer data sets as they become available.

**Methods**

**Data set.** We retrieved and organized data sets from NCBI’s Gene Expression Omnibus (GEO) and Ensemble’s ArrayExpress and the Broad Institute’s Single Cell Portal (https://portals.broadinstitute.org/single_cell). Nine data sets had sufficient tumor and non-tumor cells and were used in this study; an additional five data sets had sufficient tumor cells only and were used in testing early versions of MadHitter. Suitable data sets were identified by searching scRNASeqDB\(^{70}\), CancerSea\(^{71}\), GEO, ArrayExpress, Google Scholar, the TISCH resource (http://tisch.comp.genomics.org), and the 10x Genomics list of publications (https://www.10xgenomics.com/resources/publications/). We required that each data set contain measurements of RNA expression on single cells from human primary solid tumors of at least two patients and the metadata are consistent with the primary cancer. We did not impose any sequence depth or expression from both thresholds and included data sets from different technologies (including both SmartSeq2 and 10x). We excluded some individual patients with relatively few (typically <25) non-tumor cells depending on the size of the data set. As shown in Table 1, we excluded early data sets that had exclusively tumor cells or almost exclusively tumor cells. To our knowledge, all these samples were tumorized by experiments with target gene sets that they judged could be reasonable targets for CAR-T. They made this selection based on expression data from the Human Protein Atlas\(^{73}\) and the Genotype-Tissue Expression consortium (GTeX)\(^{74}\), which have expression information from multiple tissues which was used to identify low expressed target genes.

**Construction of target gene sets that are lowly expressed in normal tissues.** To analyze the tissue specificity of the 1269 candidate target genes, the RNA-seq data from the Human Protein Atlas (HPA) database (https://www.proteintatlas.org/about/download; Date: May 29, 2020). The HPA database includes expression values (in units of transcripts per million (TPM)) for 37 tissues from HPA (rna_tissue_hpa.tsv.zip)\(^{35}\) and 36 tissues from GTEX (Gene Expression Consortium (GTEX) rna_gtex.gct.zip).\(^{35}\)

Next, we identify target genes with low or no expression within majority of adult human tissues, for the 1269 candidate genes we identified genes whose average expression across tissues is below certain threshold value (0.25, 0.5, 1, 2, 5, and 10 TPM) in both HPA and GTEX data sets. Using the intersection of low expression candidate genes from HPA and GTEX data sets, we generated lists of high confidence targets. The size of the resulting high confidence target genes varied from 424 (average expression ≤0.25 TPM) to 900 (average expression across tissue <10 TPM) genes (Table 2). While the total number of genes decreases slowly, the decrease is much steeper if one excludes olfactory receptors and taste receptors (Table 2). These sensory receptors are not typically considered as cancer targets, although a few of these receptors are selected in initial target sets when there are few alternatives (Fig. 6). MadHitter was run on all nine data sets using the expression information from the high confidence gene lists.

**Assembling lists of membrane target genes.** We are interested in the set of genes G that (i) have the encoded protein expressed on the cell surface and (ii) for which some biochemistry lab has found a small peptide (i.e., amino acid sequences of 5–30 amino acids) that can attach itself to the target protein and get inside the cell carrying a tiny cargo of a toxic drug that will kill the cell and (iii) encode cell-surface receptors, which is necessary for RME-based therapies but not for CAR-T therapy\(^{21}\). For condition (ii), we found two review articles in the chemistry literature\(^{19,20}\) that list targets effectively meeting this...
condition. Intersecting the lists meeting conditions (i) and (ii) gave us 38 genes/ proteins that could be targeted (Table 3).

Most of the data included in Table 1 had expression data on 1200–1220 of these genes because the list of 1269 includes many olfactory receptor genes that may be omitted from standard genome-wide expression experiments. Among the 38 genes in Table 3, 13/14 data sets have all 38 genes, but GSE57872 was substantially filtered and has only 10/38 genes; since GSE57872 lacks non-tumor cells, we did not use this data set in any analyses shown.

Because the latter review was published in 2017, we expected that there are now additional genes for which ligand-mimicking peptides are known. We found 20 additional genes and those are listed in Table 4. Thus, our target set analyses restricted to genes with known ligand-mimicking peptides use 58 = 38 + 20 targets.

### Definition of the minimum hitting set problem and solution feasibility

One of Karp’s original NP-complete problems is called “hitting set” and is defined as follows. Let $U$ be a finite universal set of elements. Let $S_1, S_2, \ldots, S_n$ be subsets of $U$. Is there a small subset $H \subseteq U$ such that for $i = 1, 2, 3, \ldots, n$, $H \cap S_i$ is non-empty? In our setting, $U$ is the set of target genes and the subsets $S_i$ are the single cells. In ref. 79, numerous applications for hitting set and the closely related problems of subset cover and dominating set are described; in addition, practical algorithms for hitting set are compared on real and synthetic data.

Among the applications of hitting set and closely related NP-complete problems in biology and biochemistry are stability analysis of metabolic networks 80–83, identification of critical paths in gene signaling and regulatory networks 84–86, and selection of a set of drugs to treat cell line 85,86 or single patients 87,88. Much more information about past related work can be found in Supplementary Note 1.

Two different difficulties arising in problems such as hitting set are that (1) an instance may be intractable meaning that in the time available, one cannot either (i) prove that the instance is infeasible or (ii) find an optimal feasible solution. All instances of minimum hitting set that we considered were tractable on the NIH Biowulf system. Many instances were provably infeasible, in almost all cases, we did not plot any infeasible parameter combinations. However, in Fig. 4, the instance for the melanoma data set with the more stringent parameters was infeasible because of only one patient sample, so we omitted that patient for both parameter settings in Fig. 4.

### Basic optimal target set formulation

Given a collection $S = \{S_1, S_2, S_3, \ldots\}$ of subsets of a set $U$, the hitting set problem is to find the smallest subset $H \subseteq U$ that intersects every $S_i$ in $S$. The hitting set problem is equivalent to the set cover problem and hence is NP-complete. The following ILP formulates this target set problem: $$\min \sum_{g \in U} x(g) \quad \text{s.t.} \quad \sum_{g \in U} x(g) \geq 1 \forall S_i \in S$$

In this formulation, there is a binary variable $x(g)$ for each element $g \in U$ that denotes whether the element $g$ is selected or not. Constraint (1) makes sure that from each set $S_i$, at least one element is selected.

For any data set of tumor cells, we begin with the model that we specify a set of genes that can be targeted, and that is $U$. Each cell is represented by the subset of genes in $U$ whose expression is greater than zero. In biological terms, a cell is killed (hit) if it expresses at any level on one of the genes that is selected to be a target (i.e., in the optimal target set) in the treatment. In this initial formulation, all tumor cells are combined as if they come from one patient because we model that the treatment goal is to kill (hit) all tumor cells (all subsets). In a later subsection, we consider a fair version of this problem, taking into account that each patient is part of a cohort. Before that, we model the oncologist’s intuition that we want to target genes that are overexpressed in the tumor.

### Combining data on tumor cells and non-tumor cells

To make the hitting set formulation more realistic, we would likely model that a cell (set) is killed (hit) only if one of its targets is overexpressed compared to typical expression in non-cancer cells. Such modeling can be applied in the nine single-cell data sets that have data on non-cancer cells to reflect the principle that we would like the treatment to kill the tumor cells and spare the non-tumor cells.

Let $NT$ be the set of non-tumor cells. For each gene $g$, define its average expression $E(g)$ as the arithmetic mean among all the non-zero values of the expression level of $g$ and cells in $NT$. The zeroes are ignored because many of these likely represent dropouts in the expression measurement. Following the design of experiments in the lab of N. A., we define an expression ratio threshold factor $\alpha$ as a real number whose baseline value is 2.0. We adjust the formulation of the previous subsection, so that the set representing a cell (in the tumor cell set) contains only those genes $g$ such that the expression of $g$ is greater than $r \times E(g)$ instead of greater than zero. We keep the objective function limited to the tumor cells, but we also store a set to represent each non-tumor cell, and we tabulate which tumor cells (sets) would be killed (hit) because for at least one of the genes in the optimal target set, the expression of that gene in that non-tumor cell exceeds the threshold $r \times E(g)$. We add two continuous parameters $lb$ and $ub$ each in the range $[0,1]$ and representing, respectively, a lower bound on the proportion of tumor cells killed and an upper bound on the proportion of non-tumor cells killed. The parameters $lb$, $ub$ are only used in two constraints, and we do not favor optimal solutions that kill more tumor cells or fewer non-tumor cells, so long as the solutions obey the constraints.

More explicitly, if we let $E(g)$ be the expression level of gene $g$ in cell $C$, then $g$ is in the set of genes that can cover $C$ if and only if $E(g, C) > r \times E(g)$. We inspect this relationship for every pair of genes and cells to come up with the hitting set instance of our ILPs.

Our choice of the lower bound ($lb$) on the proportion of tumor cells killed in the range $[0.7,0.9]$ is somewhat arbitrary at this stage, but it is motivated by the widely used response evaluation criteria in solid tumors (RECIST) revised guidelines version 1.189. Those criteria include the category of partial response (PR), which is usually classified together with complete response (CR) as a responder when one makes a dichotomy between response and non-response. PR is defined as “At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.” Because volume is proportional to the cube of diameter, a 30% decrease in the diameter sum corresponds to a decrease of at least 66% in the volume, which we round up to 70% (0.7). Because the tumor mass contains both tumor cells and non-tumor cells and we want to kill the tumor cells disproportionally, we increased the baseline threshold for $lb$ to 80% (0.8) and considered values as high as 0.95 or even 0.99 in some supplementary analyses. In any case, $lb$ is a user-controlled parameter and can be set as the user of our software deems appropriate. Since most cancer treatments have some toxicity, we set the baseline value of $ub$ to the low non-zero value 0.1; in some analyses, we use the lower value 0.05. If one wanted to distinguish the different types of non-tumor cells, one could add different upper bound parameters for each cell type.

### The fair cohort target set problem for a multi-patient cohort

We want to formulate an integer linear program that selects a set of genes $S'$ from available genes in such a way that, for each patient, there exists an individual target set $H(g) \subseteq C$ of a relatively small size (compared to the optimal ITS of that patient alone that is denoted by $H(g)$).

Let $U = \{g_1, g_2, \ldots, g_38\}$ be the set of genes, where $|U|$ denotes the number of elements in the universe of genes $U$. There are $n$ patients. For the $i$th patient, we denote by $S_{npi}$ the set of cells related to patient $i$. For each tumor cell $C \in S_{npi}$, we describe it as a set of genes which is known to be targetable to cell $C$. That is, $g \in C$ if and only if a drug containing $g$ can target the cell $C$. In the ILP, there is a binary variable $x(g)$ corresponding to each gene $g \in U$ that shows whether the gene $g$ is selected or not. There is a binary variable $x(C, P(i))$ which shows whether a gene $g$ is selected in the target set of patient $P(i)$. Let $a$ be an adjustable positive integer, which we interpret as a slack for each patient’s solution. The objective function is to minimize the total number of genes selected, subject to having a target set size of at most $H(i) + a$ for patient $P(i)$ where $1 \leq i \leq n$ (constraint 2).

Constraint (3) ensures that, for patient $P(i)$, we do not select any gene that are not selected in the global set.

Constraint (4) ensures all the targets corresponding to tumor cells of patient $P(i)$ are hit.

In this ILP, there is a variable corresponding to each gene. In addition, there is a variable for each pair of gene and patient, therefore, the total number of variables is $|U|(|n| + 1)$. The total number of constraints in the form of constraints (3), (4), and (5) are $n|U|$, and $\sum_{i=1}^{n}|S_{npi}|$, respectively.

### Parameterization of the fair cohort target set problem

In the Fair Cohort Target Set ILP shown above, we give more preference towards minimizing number of genes needed in the CTS. However, we do not take into account the number of non-tumor cells killed. Killing (covering) too many non-tumor cells potentially hurts patients. To avoid that, we add an additional constraint to both the ILP for the local instances and the global instance. Intuitively, for patient $P(i)$, given an upper bound of the portion of the non-tumor cell killed $ub$, we want to find the smallest cohort target set $H(i)$ with the following properties:

1. $H(i)$ covers all the tumor cells of patient $P(i)$
2. $H(i)$ covers at most $ub \times \frac{|NT_{npi}|}{|S_{npi}|}$ where $NT_{npi}$ is the set of non-tumor cells known for patient $P(i)$; the binary variable $y(C)$ represents whether the cell $C$ is covered.
The ILP can be formulated as follows:

$$\min \sum_{g \in U} x(g)$$

$$\sum_{g \in U} x(g) \geq \sum_{v \in S_{P(i)}} 1$$ \hspace{1cm} (6)

$$\sum_{g \in U} x(g) \geq \sum_{v \in S_{P(i)}} y(C) \geq \max_{g \in U} y(g)$$ \hspace{1cm} (7)

$$\sum_{g \in S_{P(i)}} y(g) \geq \sum_{v \in S_{P(i)}} y(C) \geq \min_{u \in \{|NT_{P(i)}|\}}$$ \hspace{1cm} (8)

$$\sum_{g \in S_{P(i)}} y(g) \geq \sum_{v \in S_{P(i)}} y(C) \geq \min_{u \in \{|NT_{P(i)}|\}}$$ \hspace{1cm} (9)

In the aforementioned ILP, the total number of variables is $|U| + |S_{P(i)}| + |NT_{P(i)}|$, where there is a variable corresponding to each gene and a variable corresponding to each cell of patient $P(i)$. The total numbers of constraints in the form of constraints (7), (8), and (9) are $|S_{P(i)}|$, $|NT_{P(i)}|$, and 1, respectively. In the actual ILP implementation, constraint (8) is in fact $|U|$ different constraints for each $C \in NT_{P(i)}$.

With this formulation, the existence of a feasible solution is not guaranteed. However, covering all tumor cells might not always be necessary either as we discussed above in the context of RECIST criteria for tumor response to treatment. Hence, we add another parameter $I_b$ to let us model this scenario. In the high-level, this is the ratio of the tumor cells we want to cover. The ILP can be formulated as follows:

$$\min \sum_{g \in U} x(g)$$

$$\sum_{g \in U} x(g) \geq \sum_{v \in S_{P(i)}} 1$$ \hspace{1cm} (10)

$$\sum_{g \in S_{P(i)}} y(C) \geq I_b \sum_{v \in S_{P(i)}} 1$$ \hspace{1cm} (11)

$$\sum_{g \in S_{P(i)}} y(C) \geq \max_{g \in U} y(g)$$ \hspace{1cm} (12)

Notice that constraint (11) here is different from the one above as we only care about the total number of tumor cells covered. In the above ILP, the total number of variables in $|U| + |S_{P(i)}| + |NT_{P(i)}|$, where there is a variable corresponding to each gene and a variable corresponding to each cell of patient $P(i)$. The total numbers of constraints in the form of constraints (11), (12), and (13) are $1$, $|S_{P(i)}|$, and $1$, respectively.

Even with both $I_b$ and $I_d$, the feasibility of the ILP is still not guaranteed. However, modeling the ILP in this way allows us to parameterize the ILP for various other scenarios of interest. While the two ILPs above are designed for one patient, one can extend these ILPs for multi-patient cohort. In a way that is similar to how we define $x(g, P(i))$, the binary variable $y(C, P(i))$ denotes whether the cell $C$ is covered for the $i$th patient.

$$\min \sum_{g \in U} x(g)$$

$$\sum_{g \in U} x(g) \geq \sum_{v \in S_{P(i)}} 1$$ \hspace{1cm} (14)

$$\sum_{g \in U} x(g) \geq \sum_{v \in S_{P(i)}} y(C) \geq \max_{g \in U} y(g) \forall i \in U$$ \hspace{1cm} (15)

$$\sum_{g \in S_{P(i)}} y(C, P(i)) \geq \max_{g \in U} y(g)$$ \hspace{1cm} (16)

$$\sum_{g \in S_{P(i)}} y(C, P(i)) \geq I_b \sum_{v \in S_{P(i)}} 1$$ \hspace{1cm} (17)

$$\sum_{g \in S_{P(i)}} y(C, P(i)) \geq I_d \sum_{v \in S_{P(i)}} 1$$ \hspace{1cm} (18)

$$\sum_{g \in S_{P(i)}} y(C, P(i)) \geq \min_{u \in \{|NT_{P(i)}|\}}$$ \hspace{1cm} (19)

In the aforementioned ILP, the total number of variables is $|U| + n|U| + \sum_{i=1}^{n} |S_{P(i)}| + |NT_{P(i)}|$ where there is a variable corresponding to each gene, a variable per each pair of gene and patient, and a variable corresponding to each cell of each patient $P(i)$. The total numbers of constraints in the form of constraints (15), (16), (17), (18), and (19) are $n$, $n|U|$, $\sum_{i=1}^{n} |S_{P(i)}|$, $|U|$, $n$, and $n$, respectively.

**Implementation note, accounting for multiple optima and software and data availability.** We implemented in Python 3 the above fair cohort target set formulations, with the expression ratio $r$ as an option when non-tumor cells are available. The parameters $a$, $I_b$, $I_d$, $I_b$, $I_d$, $I_b$, $I_d$, $I_b$, $I_d$, $I_b$, $I_d$, $I_b$, $I_d$, $I_b$, $I_d$ can be set by the user in the command line. To solve the ILPs to optimality we usually used the SCIP library and its Python interface. To obtain multiple optimal solutions of equal size we used the Gurobi library (https://www.gurobi.com) and its python interface. When evaluating multiple optima, for all feasible instances, we sampled 50 optimal solutions that may or may not be distinct, using the Gurobi function select_solution(). To determine how often each gene or pair of genes occur in optimal solutions, we computed the arithmetic mean of gene frequencies and gene pair frequencies over all sampled optimal solutions.

The software package is called MadHitter. The main program is called hitting_set.py. We include in MadHitter a separate program to sample cells and generate replicates, called sample_columns.py. So long as one seeks only single optimal solutions for each instance, exactly one of SCIP and Gurobi is sufficient to use MadHitter. We verified that SCIP and Gurobi give optimal solutions of the same size. If one wants to sample multiple optima, this can be done only with the Gurobi library. The choice between SCIP and Gurobi and the number of optima to sample are controlled by command-line parameters use_gurobi and num_sol, respectively.

**Reporting summary.** Further information on research design is available in the Nature Research Reporting Summary linked to this article.

**Data availability.** Input files for all nine data sets used in most of our analyses are available without restrictions and can be found at https://ftp.ncbi.nlm.nih.gov/pub/catsMA/ MadHitter_data. The input data processed for this study have also been deposited in Zenodo [https://zenodo.org/record/6038389]. The code is written in python 3. The ILPs generated in MadHitter can be solved using either SCIP or Gurobi (www.gurobi.com). More details about the ILP packages can be found in the last subsection of "Methods" and in the file README.md on the GitHub site.

Received: 18 October 2021; Accepted: 22 February 2022; Published online: 25 March 2022

**References**

1. Von Hoff, D. D. et al. Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancers. *J. Clin. Oncol.* **28**, 4877–4883 (2010).

2. Schütte, M. et al. Cancer precision medicine: Why more is more and DNA is good. *Pub. Health Genomics* **20**, 70–80 (2017).

3. Jameson, G. S. et al. A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer. *Breast Cancer Res. Treat.* **147**, 579–588 (2014).

4. Sauri, R. et al. Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma. *Cancer Med.* **4**, 871–886 (2015).

5. Byron, S. A. et al. Prospective feasibility trial for genomics-informed treatment in recurrent and progressive glioblastoma. *Clin. Cancer Res.* **24**, 295–305 (2018).

6. Schwazer, L. et al. Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis. *JAMA Oncol.* **2**, 1452–1459 (2016).

7. Arnedos, M., Vielh, P., Soria, J. C. & Andre, F. The genetic complexity of previously treated metastatic breast cancer. *Clin. Cancer Res.* **24**, 4880–4888 (2018).

8. Nakanjam, M., Liu, S., Yang, J. & Kurzrock, R. Dosing three-drug combinations that include targeted anti-cancer agents: analysis of 3,763 patients. *Oncologist* **22**, 576–584 (2017).

9. Rebollo, J. et al. Gene expression profiling of tumors from heavily pretreated patients with metastatic cancer for the selection of therapy: a pilot study. *Am. J. Clin. Oncol.* **40**, 140–147 (2017).

10. Sureda, M. et al. Determining personalized treatment by gene expression profiling in metastatic breast carcinoma patients: a pilot study. *Clin. Trans. Oncol.* **20**, 785–793 (2018).
11. Sicklick, J. K. et al. Molecular profiling of cancer patients enables personalized combination therapy: the PREDICT study. Nat. Med. 25, 744–750 (2019).
12. Joë, J. I. et al. Realizing cancer precision medicine by integrating systems biology and nanomaterial engineering. Adv. Mater. 32, e1906783 (2020).
13. Marusyk, A. & Polyak, K. Tumor heterogeneity: causes and consequences. Biochimica et Biophysica Acta 1805, 105–110 (2010).
14. McGranahan, N. & Swanton, C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 34, 15–26 (2015).
15. Yofe, I., Dahan, R. & Amit, I. Single-cell genomic approaches for developing the next generation of immunotherapeutics. Nat. Med. 26, 171–177 (2020).
16. Neeb, S. S. et al. Axicabtagene ciloleucel CAR-T cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017).
17. Bjorn, M. J., Ding, D. & Frankel, A. Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins. Cancer Res. 45, 1241–1221 (1985).
18. Pastan, I., Willingham, M. C. & FitzGerald, D. J. P. Immunotoxins. In The next generation of immunotherapies. Mol. Syst. Biol. 15, 2068 (2019).
19. Liu, R., Li, X., Xiao, W. & Lam, K. S. Tumor-targeting peptides from combinatorial libraries. Adv. Drug Deliv. Rev. 110-111, 13–37 (2017).
20. Dannenfels, R. et al. Discriminatory power of combinatorial antigen recognition in cancer T cell therapies. Cell Syst. 11, 215–228 (2020).
21. MacKay, M. et al. The therapeutic landscape for cells engineered with chimeric antigen receptors. Nat. Biotechnology 38, 233–244 (2020).
22. Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439–448 (2018).
23. Lamers, C. H. et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol. Ther. 21, 904–912 (2013).
24. Hoffswelle, A. et al. The clinical efficacy of first-generation cariacenobryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. Cancer Immunol. Immunother. 66, 1425–1436 (2017).
25. Fedorov, V. D., Themeli, M. & Sadelain, M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptor (iCARs) divert off-target immunotherapeutic responses. Sci. Transl. Med. 5, 215ra172 (2013).
26. Grada, Z. et al. TanCAR: A novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol. Ther. Nucleic Acids 2, e105 (2013).
27. Hegde, M. et al. Combinatorial targeting offsets antigen escape and enhances effector function of adoptively transferred T cells in glioblastoma. Mol. Ther. 21, 2087–2101 (2013).
28. Roybal, K. T. et al. Engineering T cells with customized therapeutic response using synthetic Notch receptors. Cell 167, 419–443 (2016).
29. Williams, J. Z. et al. Precise T cell recognition programs designed by transcriptionally linking multiple receptors. Science 370, 1099–1104 (2020).
30. Réhová, B. Receptor-mediated targeted drug or toxin delivery. Adv. Drug Deliv. Rev. 29, 631–656 (1998).
31. Tortorella, S. & Karagianis, T. C. Transferrin receptor-mediated endocytosis: a useful target for cancer therapy. J. Membr. Biol. 247, 291–307 (2014).
32. Karp, R. M. in Complexity of Computer Computations 85–103 (Plenum Press, 1972).
33. Martinez-Veraechea, F. J. & Frenkel, D. Designing super selectivity in multivalent nano-particle binding. Proc. Natl Acad. Sci. USA 108, 10963–10968 (2011).
34. Delaney, C. et al. Combinatorial prediction of marker panels from single-cell transcriptomic data. Mol. Syst. Biol. 15, e9005 (2019).
35. Tian, X., Angioli-Uberti, S. & Battaglia, G. On the design of precision nanomedicines. Sci. Adv. eaat0919 (2020).
36. Myers, R. M. et al. Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia. J. Clin. Oncol. 39, 3044–3055 (2021).
37. Caron, M. et al. Single-cell analysis of childhood leukemia reveals a link between developmental states and ribosomal protein expression as a source of intra-individual heterogeneity. Sci. Rep. 10, 8079 (2020).
38. Müller, S. et al. A role for receptor tyrosine phosphorylation zeta in glioma cell migration. Oncogene 22, 661–668 (2003).
39. Ulbricht, U. et al. Expression and function of the receptor protein tyrosine phosphorylation zeta and its ligand pleiotrophin in human astrocytomas. J. Neurochem. Exp. Neurol. 62, 1265–1277, 8699–8702 (2012).
40. Chen, H. M. et al. Enhanced expression and phosphorylation of the MET oncogene by glioma-specific PTPRZ1-MET fusions. FEBS Lett. 589, 1437–1443 (2015).
41. Ulbricht, U., Eicher, C., Fiharbrand, R., Westphal, M. & Lamszus, K. RNA interference heterogeneity in cancer evolution. J. Neurochem. 98, 1497–1506 (2006).
42. Bourgon, A. M. et al. Intracellular and extracellular domains of protein tyrosine phosphoryse (PTP) and its differential regulation glioma cell growth and motility. Oncotarget 5, 8699–8702 (2014).
43. Fujikura, A. et al. Targeting PTPRZ inhibits stem cell-like properties and tumorigenicity in glioblastoma cells. Sci. Rep. 7, 5609 (2017).
44. Pastor, M. et al. Development of inhibitors of receptor protein tyrosine phosphoryse (PTP) as candidates for CNS disorders. Eur. J. Med. Chem. 144, 318–329 (2017).
45. Ilmarinen, S. et al. Single-cell RNA-Seq analysis of infiltrating neoplastic cells at the migrating front of human glioblastoma. Cell Rep. 21, 1399–1410 (2017).
46. Bergelson, J. M. et al. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275, 1320–1323 (1997).
47. Nilchian, A. et al. CXADR-mediated formation of an AKT inhibitory signaling module at tight junctions controls epidermal-mesenchymal plasticity in breast cancer. Cancer Res. 79, 47–60 (2019).
48. Arfelt, K. N. et al. Signaling via G proteins mediates tumorigenic effects of PGRP7. Cell. Signal. 30, 9–18 (2017).
49. Zhang, Y., Qian, Y., Lu, W. & Chen, X. The G protein-coupled receptor 87 is necessary for p53-dependent cell survival in response to genotoxic stress. Oncogene 32, 443 (2016).
76. Gainer-Dewar, A. & Vera-Licona, P. The minimal hitting set generation problem: Algorithms and computation. *SIAM J. Discr. Math.* **31**, 63–100 (2017).

77. Haedike, O. & Klamt, S. Computing complex metabolic intervention strategies using constrained minimal cut sets. *Metab. Eng.* **13**, 204–213 (2011).

78. Haus, U.-U., Klamt, S. & Stephan, T. Computing knock-out strategies in metabolic networks. *J. Comput. Biol.* **15**, 259–268 (2008).

79. Jerby-Arnon, L. et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. *Nat. Med.* **17**, 1611–1624 (2011).

80. Keren Yizhak, and Sushant Patkar for assistance in identifying and retrieving suitable single-cell RNA-seq data sets. Thanks to Leandro Hermida for technical advice.

81. Trinh, C. T., Wlaschin, A. & Srienc, F. Elementary mode analysis: a useful metabolic pathway analysis tool for characterizing cellular metabolism. *Appl. Microbiol. Biotechnol.* **81**, 813–826 (2009).

82. Ideker, T. Discovery of regulatory interactions through perturbation: inference and experimental design. *Pac. Symp. Biocomput.* 5, 302–313 (2000).

83. Wang, R. S. & Albert, R. Elementary signaling modes predict the essentiality of signal transduction network components. *BMC Syst. Biol.* 5, 44 (2011).

84. Zvedei-Oancea, I. & Schuster, S. A theoretical framework for detecting signal transfer routes in signaling networks. *Comput. Chem. Eng.* **29**, 597–617 (2005).

85. Vazquez, A. Optimal drug combinations and minimal hitting sets. *BMC Syst. Biol.* 3, 81 (2009).

86. Mellor, D., Prieto, E., Mathieson, L. & Moscato, P. A kernelisation approach for multiple d-hitting set and its application in optimal multi-drug therapeutic combinations. *PLoS ONE* 5, e13055 (2010).

87. Vera-Licona, P., Bonnet, E., Brillot, E. & Zinovyev, A. OSCANA: optimal combinations of interventions from network analysis. *Bioinformatics* 29, 1571–1573 (2013).

88. Pang, K. et al. Combinatorial therapy discovery using mixed integer linear programming. *Bioinformatics* **30**, 1456–1463 (2014).

89. Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur. J. Cancer* **45**, 228–247 (2009).

90. Jerby-Arnon, L. et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. *Cell* 175, 984–997 (2018), e24.

91. Achterberg, T. SCIP: Solving constraint integer programs. *Math. Program.* **1571**, 997 (2018). e24.

92. Pang, K. et al. Combinatorial therapy discovery using mixed integer linear programming. *Bioinformatics* **30**, 1456–1463 (2014).

93. Chung, W. et al. Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. *Nat. Commun.* **8**, 15081 (2017).

94. Venteicher, A. S. et al. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. *Science* **355**, pii:eaai8478 (2017).

95. Venteicher, A. S. et al. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. *Science* **355**, pii:eaai8478 (2017).

96. Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. *Science* **344**, 1396–1401 (2014).

97. Filbin, M. G. et al. Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. *Science* **360**, 331–335 (2018).

98. Li, H. et al. Reference component analysis of single-cell transcriptomes elucidates cellular heterogeneity in human colorectal tumors. *Nat. Genet.* **49**, 708–718 (2017).

99. Puram, S. V. et al. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. *Cell* **171**, 1611–1624 (2017), e24.

100. Shih, A. J. et al. Identification of grade and origin specific cell populations in serous epithelial ovarian cancer by single cell RNA-seq. *PLoS ONE* **13**, e0208778 (2018).

101. Miyamoto, D. T. et al. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. *Science* **349**, 1351–1356 (2015).

102. Lambrechts, D. et al. Phenotype molding of stromal cells in the lung tumor microenvironment. *Nat. Med.* **24**, 1277–1289 (2018).

**Acknowledgements**

This research is supported in part by the Intramural Research program of the National Institutes of Health, National Cancer Institute. This research is supported in part by the University of Maryland Year of Data Science Program. This research is supported in part by start-up funds from Northwestern University (S.A., P.S., S.K) and a research award from Amazon to support the research of S.K. This work utilized the computational resources of the NIH HPC Biowulf cluster (http://hpc.nih.gov). Thanks to E. Michael Gertz for technical assistance with SCIP, Gurobi, and Biowulf. Thanks to Allon Wagner, Keren Yizhak, and Sushant Patkar for assistance in identifying and retrieving suitable single-cell RNA-seq data sets. Thanks to Leandro Hermida for technical advice.

**Author contributions**

Conceptualization of the study: S.A., P.S., N.A., S.K, A.A.S., and E.R. Data curation: S.A., P.S., R.V., and A.A.S. Formal data analysis: S.A., P.S., R.V., S.S., F.S., and A.A.S. Developed methods: S.A., P.S., R.V., A.A.S., and E.R. Software design and implementation: S.A. and P.S. Software testing: S.A., P.S., R.V., and A.A.S. Visualization: S.A., P.S., R.V., S.S., and F.S. Writing: S.A., P.S., R.V., A.A.S., and E.R. Editing: S.A., P.S., R.V., S.S., F.S., N.A., S.K., A.A.S., and E.R. Supervised the work of S.A. and P.S. S.K. Supervised the study: A.A.S. and E.R.

**Funding**

Open Access funding provided by the National Institutes of Health (NIH).

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Supplementary information** The online version contains supplementary material available at https://doi.org/10.1038/s41467-022-29154-2.

**Correspondence** and requests for materials should be addressed to Alejandro A. Schäffer or Eytan Ruppin.

**Peer review information** *Nature Communications* thanks Paola Vera-Licona and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

**Reprints and permission information** is available at http://www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.